These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24801834)

  • 21. Adoptive transfer of Mammaglobin-A epitope specific CD8 T cells combined with a single low dose of total body irradiation eradicates breast tumors.
    Lerret NM; Rogozinska M; Jaramillo A; Marzo AL
    PLoS One; 2012; 7(7):e41240. PubMed ID: 22911764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L.
    Díaz-Montero CM; Zidan AA; Pallin MF; Anagnostopoulos V; Salem ML; Wieder E; Komanduri K; Montero AJ; Lichtenheld MG
    Immunol Res; 2013 Dec; 57(1-3):23-33. PubMed ID: 24218360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
    Rolle CE; Carrio R; Malek TR
    Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.
    Tatum AM; Mylin LM; Bender SJ; Fischer MA; Vigliotti BA; Tevethia MJ; Tevethia SS; Schell TD
    J Immunol; 2008 Sep; 181(6):4406-17. PubMed ID: 18768900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
    Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
    Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma.
    Miller CH; Graham L; Bear HD
    BMC Immunol; 2010 Nov; 11():54. PubMed ID: 21050466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle.
    Zhang Q; Yang XJ; Kundu SD; Pins M; Javonovic B; Meyer R; Kim SJ; Greenberg NM; Kuzel T; Meagher R; Guo Y; Lee C
    Mol Cancer Ther; 2006 Jul; 5(7):1733-43. PubMed ID: 16891459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
    Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
    Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.
    Klyushnenkova EN; Riabov VB; Kouiavskaia DV; Wietsma A; Zhan M; Alexander RB
    Prostate; 2014 Oct; 74(14):1423-32. PubMed ID: 25111463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model.
    Bourquin C; von der Borch P; Zoglmeier C; Anz D; Sandholzer N; Suhartha N; Wurzenberger C; Denzel A; Kammerer R; Zimmermann W; Endres S
    J Immunol; 2010 Aug; 185(4):2580-8. PubMed ID: 20644173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer.
    Bransi A; Salgado OC; Beffinger M; Milo K; Silina K; Yagita H; Becher B; Knuth A; van den Broek M
    Cancer Immunol Res; 2015 Nov; 3(11):1279-88. PubMed ID: 26141620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model.
    Wada S; Harris TJ; Tryggestad E; Yoshimura K; Zeng J; Yen HR; Getnet D; Grosso JF; Bruno TC; De Marzo AM; Netto GJ; Pardoll DM; DeWeese TL; Wong J; Drake CG
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):769-76. PubMed ID: 24064321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors.
    Yorty JL; Tevethia SS; Schell TD
    Cancer Immunol Immunother; 2008 Jun; 57(6):883-95. PubMed ID: 18004562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
    Winter H; Hu HM; McClain K; Urba WJ; Fox BA
    J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine.
    Abrams SI; Hodge JW; McLaughlin JP; Steinberg SM; Kantor JA; Schlom J
    J Immunother; 1997 Jan; 20(1):48-59. PubMed ID: 9101413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8
    Johnson CB; May BR; Riesenberg BP; Suriano S; Mehrotra S; Garrett-Mayer E; Salem ML; Jeng EK; Wong HC; Paulos CM; Wrangle JM; Cole DJ; Rubinstein MP
    Cancer Res; 2018 Jun; 78(11):3067-3074. PubMed ID: 29636345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy.
    Furusawa A; Reiser J; Sadashivaiah K; Simpson H; Banerjee A
    J Immunother; 2018; 41(2):53-63. PubMed ID: 29271784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer.
    Anderson MJ; Shafer-Weaver K; Greenberg NM; Hurwitz AA
    J Immunol; 2007 Feb; 178(3):1268-76. PubMed ID: 17237372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.